PDCD1 and neoplasm: Overall, consistent with the findings from our in vitro experiments, the results from in vivo xenograft models confirmed that the engineering of T cells to secrete IL-12 from the PDCD1 locus can profoundly enhance the anti-tumor activity of NY-ESO-1-specific TCR-T cells.